| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
The two domains in clinical pharmacology dealing with optimizing dosing recommendations are pharmacokinetics and pharmacodynamics. However, the usefulness of these disciplines is limited if viewed in isolation. Pharmacokinetic/pharmacodynamic (PK/PD) relationships and modeling builds the bridge between these two classical disciplines of clinical pharmacology. It links the concentration-time profile as assessed by pharmacokinetics to the intensity of observed response as quantified by pharmacodynamics. Thus, the resulting so-called integrated PK/PD-models allow the description of the complete time course of the desired and/or undesired effects in response to a drug therapy. PK/PD-modeling can elucidate the causative relationship between drug exposure and response and provide a better understanding of the sequence of events that result in the observed drug effect. This information can then be used to streamline the drug development process and dose optimization. This consensus paper presents an update on the current state of PK/PD-modeling from an academic, industrial and regulatory perspective.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Yamazaki, J. Skaptason, D. Romero, J. H. Lee, H. Y. Zou, J. G. Christensen, J. R. Koup, B. J. Smith, and T. Koudriakova Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models Drug Metab. Dispos., July 1, 2008; 36(7): 1267 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. H. Huntjens, M. Danhof, and O. E. Della Pasqua Pharmacokinetic pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors Rheumatology, July 1, 2005; 44(7): 846 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Muller, A. dela Pena, and H. Derendorf Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1441 - 1453. [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Daw, V. M. Santana, L. C. Iacono, W. L. Furman, D. R. Hawkins, P. J. Houghton, J. C. Panetta, A. J. Gajjar, and C. F. Stewart Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., March 1, 2004; 22(5): 829 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Colburn Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing J. Clin. Pharmacol., April 1, 2003; 43(4): 329 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Buijs, J. Burggraaf, J. G. Langendonk, R. C. Schoemaker, M. Frolich, J.-W. Arndt, A. F. Cohen, J. A. Romijn, M. T. Ackermans, H. P. Sauerwein, et al. Hyposomatotropism Blunts Lipolysis in Abdominally Obese Women J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3851 - 3858. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
